Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The question which is bugging me..

Why would the commercialization agreement preclude PTSC Management from commenting on the reexamination of a patent? It has been a while since I have read the agreement, realize it prohibits PTSC Management from speaking about the licensing efforts for the MMP without first getting approval from TPL, but I don't remember it stating anything about USPTO and validity. Lets say the '336 is recertified (looks to be the case), do we need approval in your opinion to PR the event? TIA

Good luck everyone.

Share
New Message
Please login to post a reply